1999～2003年铜绿假单胞菌耐药性变迁的分析  

Drug Resistance Diversity of Pseud omonas aeruginosa Clinical Isolates:Analysis from 1999 to 2003

作　　者：郭晨雯[1] 范春[1] 牛其昌[1] 傅金英[1] 王颖[1] 

机构地区：[1]青岛市人民医院,山东青岛266001

出　　处：《中华医院感染学杂志》2005年第8期940-942,共3页Chinese Journal of Nosocomiology

摘　　要：目的研究1999～2003年铜绿假单胞菌临床分离株对常用抗菌药物耐药率的变迁,为合理使用抗菌药物提供依据. 方法回顾分析1999～2003年我院住院患者所有分离株,药敏试验采用K-B纸片扩散法. 结果铜绿假单胞菌对常用抗菌药物的耐药率有逐年增高的趋势;哌拉西林从1999年的17.6%增至2003年的79.2%,对头孢他啶的耐药率2003年增至46.2%;对头孢哌酮/舒巴坦的耐药率最低(6.3%). 结论铜绿假单胞菌是医院感染常见条件致病菌,其耐药问题已十分突出,应严格限制抗菌药物的使用.对铜绿假单胞菌感染的治疗,可首选头孢哌酮/舒巴坦、哌拉西林/他唑巴坦、环丙沙星、亚胺培南等,β-内酰胺类+阿米卡星为较优化的组合治疗方案.OBJECTIVE To study drug resistance diversity of Pseudomonas aeruginosa from 1999 to 2003. METHODS A total of 244 clinical P. aeruginosa isolates were detected and retrospectively analyzed. Antimicrobial susceptibility testing was performed using Kirby-Bauer method. RESULTS The drug resistance rates of P. aeruginosa were increased rapidly by years. The resistance rate to piperacillin raised from 17.6％ of 1999 to 79.2 ％ of 2003. The resistance rate to ceftazidime reached to 46.2 ％ at 2003. The resistance rate to cefoperazone/sulbactam was the lowest（6.3 ％）. CONCLUSIONS P. aeruginosa is one of the common pathogens in clinics. The problem of antibiotics resistance is very prominent. The use of antibiotics should be limited strictly. With the patient infected by P. aeruginosa, it should be first treated experientially by cefoperazone/sulbactam, piperacillin/tazobactam, ciprofloxacin, imipenem, et al. The combination of β-lactam antibiotics and amikacin, such as piperacillin plus amikacin, is a rational therapeutic regimen.

关 键 词：铜绿假单胞菌 耐药性 抗菌药物 

分 类 号：R378.991[医药卫生—病原生物学]